EN
抗体药类似物
Research Grade Rinucumab
All
  • CatalogTD-HY260016
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsREGN-2176,REGN-2176-3(combinationofafliberceptandricunumab),REGN2176,CAS:1569263-06-4
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Rinucumab


Catalog No. TD-HY260016
Species reactivity Human
Applications Research Grade Biosimilar
Host species Human
Isotype IgG4-kappa
Expression system Mammalian Cells
Clonality Monoclonal
Target Beta-type platelet-derived growth factor receptor, Beta platelet-derived growth factor receptor, CD140b, Platelet-derived growth factor receptor 1, PDGFRB, PDGF-R-beta, Platelet-derived growth factor receptor beta, CD140 antigen-like family member B, PDGFR-1, PDGFR1, PDGFR-beta, PDGFR
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession P09619
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names REGN-2176,REGN-2176-3(combinationofafliberceptandricunumab),REGN2176,CAS:1569263-06-4
Background Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration.
Note For research use only. Not for use in clinical or therapeutic applications.